SynthesisInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2015
The expression of tumor-derived and stromal-derived matrix metalloproteinase 2 predicted prognosis of ovarian cancer.
Synthesis in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Clinical significance of matrix metalloproteinase-2 in endometrial cancer: A systematic review and meta-analysis.Medicine · 2018Pooled it
- Review
- USP4 promotes proliferation and metastasis in human lung adenocarcinoma.Scientific reports · 2025Article
- Role of extracellular vesicles in cancer: implications in immunotherapeutic resistance.Frontiers in immunology · 2025Review
- A Subset of Secreted Proteins in Ascites Can Predict Platinum-Free Interval in Ovarian Cancer.Cancers · 2022Article
- Expression of metalloproteinases MMP-2 and MMP-9 is associated to the presence of androgen receptor in epithelial ovarian tumors.Journal of ovarian research · 2020Article
- The prognostic values of matrix metalloproteinases in ovarian cancer.The Journal of international medical research · 2020Article
- circPUM1 Promotes Tumorigenesis and Progression of Ovarian Cancer by Sponging miR-615-5p and miR-6753-5p.Molecular therapy. Nucleic acids · 2019Article
- Matrix Metalloproteinase Expressions Play Important role in Prediction of Ovarian Cancer Outcome.Scientific reports · 2019Article
- Cancer-Associated Fibroblasts Build and Secure the Tumor Microenvironment.Frontiers in cell and developmental biology · 2019Review
- The Air Sac Primordium ofInternational journal of molecular sciences · 2018Review
- The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression.International journal of molecular sciences · 2018Review
- Relationship between matrix metalloproteinases and the occurrence and development of ovarian cancer.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2017Review
- A pan-cancer analysis of secreted Frizzled-related proteins: re-examining their proposed tumour suppressive function.Scientific reports · 2017Article
- Promotion of breast cancer cells MDA-MB-231 invasion by di(2-ethylhexyl)phthalate through matrix metalloproteinase-2/-9 overexpression.Environmental science and pollution research international · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the association of tumor-derived matrix metalloproteinase 2 (MMP-2) and stromal-derived MMP-2 expression with the prognosis of patients with ovarian cancer, a meta-analysis study was performed, which was aimed to comprehensively review the evidence of MMP-2 as prognostic biomarkers in ovarian cancers.
methodsAll relevant studies were searched in PubMed and Web of Science until May 30, 2014. Hazard ratios (HRs) with their 95% confidence intervals (CIs) were used to assess the association between MMP-2 expression (tumor-derived or stromal-derived) and prognosis of patients with ovarian cancer. Pooled odds ratios (ORs) and their 95% CIs were used to assess the correlation of MMP-2 expression with the clinicopathological features of patients with ovarian cancer.
resultsA total of 965 patients in 8 studies were included in this analysis. Among them, tumor-derived and stromal-derived MMP-2 expression was detected in 7 and 5 articles, respectively. The results revealed that ovarian cancer patients with positive tumor-derived MMP-2 expression showed a worse prognosis than did the ones with negative tumor-derived MMP-2 expression (HR, 1.52; 95% CI, 1.06-2.20). However, ovarian cancer patients with positive stromal-derived MMP-2 expression had not. In addition, we also found that tumor-derived MMP-2 expression was associated with distant metastasis (absent vs present; pooled OR, 4.52; 95% CI, 1.56-13.09; P = 0.001).
conclusionsThese results suggested that positive tumor-derived MMP-2 expression could predict a lower overall survival rate and could be an independent dangerous prognostic factor in patients with ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.